StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Earnings

Eli Lilly's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$24.40B
+38.6% on a year earlier
non-GAAP, Q3 FY2026
$7.48
$7.02 a year earlier
Latest guidance
Issued
Oct 29, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Eli Lilly's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 3, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026before the open$24.40B+38.6%$7.22$7.48Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$23.00B+47.8%$7.94$8.38Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026before the open$19.80B+55.5%$8.26$8.55Release
Q4 FY2025ended Dec 31, 2025Feb 4, 2026before the open$19.29B+42.9%$7.39$7.54Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025before the open$17.60B+53.9%$6.21$7.02Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$15.56B+37.7%––Release
Q1 FY2025ended Mar 31, 2025May 1, 2025before the open$12.73B+45.2%$3.06$3.34Release
Q4 FY2024ended Dec 31, 2024Jan 14, 2025before the open$13.50B+44.4%––Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$11.44B+20.4%$1.07$1.18Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$11.30B+36.0%$3.28$3.92Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024before the open$8.77B+26.0%$2.48$2.58Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Eli Lilly's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueGAAPFY2026$91.00B – $92.00B–NewOct 29, 2026
RevenueGAAPFY2026$85.00B – $87.00B–NewAug 5, 2026
RevenueFY2026$82.00B – $85.00B$80.00B – $83.00BRaisedApr 30, 2026
Performance Marginnon-GAAPFY202652% – 52.5%–NewOct 29, 2026
Earnings per Sharenon-GAAPFY2026$35.00 – $36.00–NewOct 29, 2026
Earnings per Sharenon-GAAPFY2026$35.50 – $36.50$35.50 – $37.00LoweredAug 5, 2026
Performance Marginnon-GAAPFY202649% – 50.5%47% – 48.5%RaisedAug 5, 2026
Tax Ratenon-GAAPFY202619% – 20%–NewOct 29, 2026
Tax Ratenon-GAAPFY202618% – 19%18% – 19%LoweredApr 30, 2026

Guidance vs results

The last range Eli Lilly gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$63.00B – $63.50B$65.18BΣ4QAbove range

Guidance history

Every forecast Eli Lilly put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026Earnings per ShareFY2026$35.00 – $36.00New
Oct 29, 2026Performance MarginFY202652% – 52.5%New
Oct 29, 2026Tax RateFY202619% – 20%New
Oct 29, 2026RevenueFY2026$91.00B – $92.00BNew
Aug 5, 2026Earnings per ShareFY2026$35.50 – $36.50Lowered
Aug 5, 2026Performance MarginFY202649% – 50.5%Raised
Aug 5, 2026RevenueFY2026$85.00B – $87.00BNew
Apr 30, 2026Earnings per ShareFY2026$35.50 – $37.00Raised
Apr 30, 2026Performance MarginFY202647% – 48.5%Raised
Apr 30, 2026Tax RateFY202618% – 19%Lowered
Apr 30, 2026RevenueFY2026$82.00B – $85.00BRaised
Feb 4, 2026Earnings per ShareFY2026$33.50 – $35.00New
Feb 4, 2026Performance MarginFY202646% – 47.5%New
Feb 4, 2026Tax RateFY202618% – 19%Lowered
Feb 4, 2026RevenueFY2026$80.00B – $83.00BNew
Oct 30, 2025EPS guidanceFY2025$23.00 – $23.70Raised
Oct 30, 2025EPS guidanceFY2025$21.80 – $22.50Raised
Oct 30, 2025performance marginFY202545% – 46%Raised
Oct 30, 2025performance marginFY202543.5% – 44.5%Raised
Oct 30, 2025full-year revenue guidanceFY2025$63.00B – $63.50BRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Eli Lilly filed with the SEC as exhibits to Form 8-K or 6-K

  1. Refer to: Megan MacCauley; [email protected] (Media)
    Results
  2. Refer to: Megan MacCauley; [email protected] (Media)
    Results
  3. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  4. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  5. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  6. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  7. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  8. Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media)
    Results
  9. Refer to: Carrie Munk; [email protected] ; 317-416-2393 (Media)
    Results
  10. Refer to: Jordan Bishop; [email protected]; (317) 374-1878 (Media)
    Results
  11. Refer to: Jordan Bishop; [email protected]; (317) 374-1878 (Media)
    Results
  12. Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media)
    Results
  13. Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media)
    Results
  14. Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media)
    Results
  15. Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media)
    Results